Asked by: Wendy Morton (Conservative - Aldridge-Brownhills)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health and Social Care, with reference to HCWS1271 of 26 January 2026t on Improving Cancer Care and Early Diagnosis, when the National Cancer Plan will be published; what interim milestones have been set ahead of publication; what engagement has taken place with NHS England, Cancer Alliances and patient groups; and what mechanisms will be used to ensure delivery against the Plan’s commitments.
Answered by Ashley Dalton - Parliamentary Under-Secretary (Department of Health and Social Care)
The National Cancer Plan was published on the 4 February 2026.
The Department received more than 11,000 responses to a Call for Evidence alongside significant engagement with patients, families, carers, clinicians, researchers, cancer charities and voluntary groups.
Now that the National Cancer Plan is published, the Department, NHS England and the Cancer Alliances will continue to work together with partners across the healthcare landscape to ensure it is delivered, to transform cancer care and save lives.
The Government has committed to a clear accountability structure for the plan, where Cancer Alliances play a leading role to deliver it, working with local systems. A reformed National Cancer Board, jointly chaired by the Department and an independent representative, will track progress against the Plans commitments and provide regular updates to ministers. The plan includes tables at the end of each chapter, setting out when commitments should be delivered and which organisation will be responsible.
Asked by: Grahame Morris (Labour - Easington)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health and Social Care, what assessment his Department has made of the potential implications for its policies of the report by the Institute of Alcohol Studies entitled Now You See It, Now You Don't, published on 29 January 2026.
Answered by Ashley Dalton - Parliamentary Under-Secretary (Department of Health and Social Care)
The Government recognises the harms associated with alcohol consumption and has taken crucial steps in the 10-Year Health Plan to support people to make healthier choices. There is a balance to be struck, and the Government continues to consider carefully what other measures might be needed to turn the tide on alcohol harms, while continuing to support economic growth.
Currently, alcohol advertisements follow voluntary codes, regulated by the Advertising Standards Authority (ASA). The ASA’s Advertising Codes contain specific rules about how alcohol can be advertised, as they recognise the social imperative of ensuring that alcohol advertising is responsible.
The Department of Health and Social Care continues to work with the Department for Digital, Culture, Media and Sport, as the lead Government department responsible for advertising, to consider if additional statutory restrictions on marketing and advertising are needed to reduce alcohol related harms.
Asked by: Jerome Mayhew (Conservative - Broadland and Fakenham)
Question to the Department for Transport:
To ask the Secretary of State for Transport, what discussions her Department has had with the Department of Health and Social Care on promoting regular sight tests for drivers as part of the Government’s road safety strategy.
Answered by Lilian Greenwood - Government Whip, Lord Commissioner of HM Treasury
Both Department for Transport and Driving and Vehicle Licensing Agency officials have worked with officials from the Department of Health and Social Care (DHSC) while developing the proposed changes to eyesight testing for older drivers, and we will continue to engage with the DHSC as our policies develop further.
The Department for Transport fully supports the NHS’s recommendation that adults should have their eyes tested every two years.
All drivers, regardless of age, have a legal responsibility to inform the Driver and Vehicle Licensing Agency (DVLA) if they develop a medical condition that may affect their ability to drive.
On 7 January 2026 we published our new Road Safety Strategy, setting out our vision for a safer future on our roads for all. Alongside the strategy, we launched five consultations including a consultation on introducing mandatory eyesight testing for older drivers.
Once the consultation has concluded, we will publish our response in due course.
Asked by: Clive Jones (Liberal Democrat - Wokingham)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health and Social Care, what provision the National Cancer Plan will make for orphan drug pathways for patients with rare cancers requiring personalised treatment plans; and how those pathways will differ from existing commissioning arrangements.
Answered by Ashley Dalton - Parliamentary Under-Secretary (Department of Health and Social Care)
On 4 February 2026, NHS England and the Department published a National Cancer Plan for England. The National Cancer Plan is part of our work to build a National Health Service that is fit for the future and will make England a world-leader for cancer survival.
The orphan drug designation is assessed by the Medicines and Healthcare products Regulatory Agency and is granted at the same time as the marketing authorisation. It provides a period of market exclusivity during which similar competitor medicines cannot enter the United Kingdom market. The orphan drug regulations are designed to support the development of medicines to treat rare diseases including rare cancers.
All new licensed medicines, including orphan medicines, are evaluated by the National Institute for Health and Care Excellence (NICE), which makes recommendations for the NHS on whether they represent a clinically and cost-effective use of NHS resources. NICE aims wherever possible to issue recommendations on new medicines close to the time of licensing, and the NHS in England is legally required to fund medicines recommended by NICE. NICE has a strong track record in recommending orphan medicines for use on the NHS and many thousands of patients with rare diseases have benefitted from access to new medicines as a result.
The Rare Cancers Bill, currently going through the House of Lords, places a duty on the Government to publish a review of the law related to marketing authorisation for rare cancer drugs, for instance orphan drugs for cancer, comparing the UK’s approach to other approaches internationally. Through the National Cancer Plan the Government has committed to full implement of the Rare Cancers Bill to streamline trial pathways and review regulatory barriers that prevent access to promising new treatments.
Asked by: Stuart Anderson (Conservative - South Shropshire)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health and Social Care, when he plans to reply to the email from the hon. Member for South Shropshire dated 24 October 2025 with case reference number SA36602.
Answered by Zubir Ahmed - Parliamentary Under-Secretary (Department of Health and Social Care)
The Department has received the Hon. Member’s letter and I will respond shortly.
Asked by: Lee Dillon (Liberal Democrat - Newbury)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health and Social Care, what assessment his Department has made of the adequacy of the performance of AJM Healthcare in delivering wheelchair services to the NHS.
Answered by Zubir Ahmed - Parliamentary Under-Secretary (Department of Health and Social Care)
The safety of all patients, whether they are treated in the National Health Service or the independent sector, is a top priority for the Government. There are a range of providers of NHS wheelchair services across England. Integrated care boards (ICBs) are responsible for monitoring service provision and effectively managing contracts with their commissioned providers.
NHS England are aware there have been a number of separate complaints about the quality of services provided by AJM Healthcare, which are being dealt with on an individual basis by the Ombudsman’s office. NHS England has flagged this to the relevant ICBs, who are responsible for the provision and commissioning of local wheelchair services. NHS England supports ICBs to make improvements and commission effective, efficient, and personalised wheelchair services. Actions taken include:
- establishing a national wheelchair dataset, where data has been collected quarterly from ICBs, formerly clinical commissioning groups, since July 2015 and which supports the drive for improvements in wheelchair services. This data looks at waiting times across the pathway to enable targeted action if improvement is required. Further information is available at the following link:
https://www.england.nhs.uk/statistics/statistical-work-areas/national-wheelchair/
- the Wheelchair Quality Framework, which was published on the 9 April 2025, and which was co-produced with key stakeholders, including Whizz Kids. The framework sets out quality standards and statutory requirements for ICBs, such as offering personal wheelchair budgets, with further information available at the following link:
https://www.england.nhs.uk/long-read/wheelchair-quality-framework/
- personal wheelchair budgets, with NHS England having introduced personal wheelchair budgets, including in legal rights, in 2019, providing a clear framework for ICBs to commission personalised wheelchair services which are outcomes focused and integrated. Personal wheelchair budgets give people greater choice over the wheelchair provided, with further information available at the following link:
https://www.england.nhs.uk/publication/guidance-on-the-legal-rights-to-have-personal-health-budgets-and-personal-wheelchair-budgets/
Asked by: Max Wilkinson (Liberal Democrat - Cheltenham)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health and Social Care, what progress the MRS has made in delivering mechanistic research into ME/CFS.
Answered by Zubir Ahmed - Parliamentary Under-Secretary (Department of Health and Social Care)
We do not know what ‘MRS’ refers to in this context. The Department funds research through the National Institute for Health and Care Research (NIHR). A limited amount of mechanistic research is funded through the NIHR, but the majority of mechanistic research is funded through the Medical Research Council (MRC), a UK Research and Innovation Council sponsored by the Department for Science, Innovation and Technology. Mechanistic research into myalgic encephalomyelitis, also known as chronic fatigue syndrome, is within the remit of the MRC.
Asked by: Jo Platt (Labour (Co-op) - Leigh and Atherton)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health and Social Care, in response to Question tabled on 15 December 2025, UIN 99871, if the Government can outline what steps are being taken to ensure the needs of people with severe Myalgic Encephalomyelitis are adequacy met.
Answered by Ashley Dalton - Parliamentary Under-Secretary (Department of Health and Social Care)
The final delivery plan on myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS), published in July 2025, includes an action for the Department and NHS England to explore whether a specialised service should be prescribed by my Rt. Hon. Friend, the Secretary of State for Health and Social Care, for severe ME/CFS. Officials from the Department have commenced discussions with NHS England on how best to take forward this action.
The third and final session in NHS England’s newly-developed ME/CFS e-learning series, Managing Severe ME/CFS, is now live on the NHS Learning Hub. This session provides practical, evidence-based guidance for healthcare professionals to support people living with severe and very severe ME/CFS.
Additionally, as set out in the Plan for Change, we are committed to returning to the NHS constitutional standard that 92% of patients wait no longer than 18 weeks from referral to consultant-led treatment by March 2029. We exceeded our pledge to deliver an extra two million appointments, tests, and operations in our first year of government, having delivered 5.2 million additional appointments between July 2024 and June 2025. This will help people with severe ME/CFS to get support sooner.
The 10-Year Health Plan sets out a transformed vision for elective care by 2035, where most interactions no longer take place in a hospital building, instead happening virtually or via neighbourhood services. We will empower patients by giving them greater choice and control and establishing expected standards for making their experience of planned NHS care as smooth, supportive and convenient as possible, including for people with severe ME/CFS.
Asked by: Tom Hayes (Labour - Bournemouth East)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health and Social Care, what steps is the Department taking to remove barriers preventing community homelessness health services, such as mobile clinics, from accessing NHS SystemOne records.
Answered by Ashley Dalton - Parliamentary Under-Secretary (Department of Health and Social Care)
It is important that community health teams can access the information they need to provide quality care, including for people who are experiencing homelessness. NHS England and the Phoenix Partnership (TPP), the company that provides SystemOne, already offer several routes for some clinicians to view records outside of GP settings.
These include national services such as GP Connect and the National Care Records Service (NCRS), which allow clinicians to see key information from GP records. NCRS can also be used on mobile devices such as iPads. Integrated care systems are rolling out Shared Care Records, which give clinicians wider access to both GP and secondary care records, where appropriate.
More broadly, the Government’s commitments to improve health outcomes for people experiencing homelessness are set out in the cross-government strategy, A National Plan to End Homelessness. Through this strategy, we are working with NHS England, local authorities, and third sector partners to strengthen integrated care pathways. This includes improving collaboration between primary care, outreach teams, and community services. More information about the strategy is available at the following link:
The Single Patient Record will enable improvements as it will provide a comprehensive view of health and care information across care settings. It will give both patients and professionals secure access to a single, accurate and up-to-date record – wherever and whenever it's needed.
Asked by: Cat Smith (Labour - Lancaster and Wyre)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health and Social Care, what plans his Department has to publish updated guidance on managing conflicts of interest between civil servants and Ministers in relation to unhealthy commodity industries.
Answered by Ashley Dalton - Parliamentary Under-Secretary (Department of Health and Social Care)
The Department already has established arrangements in place to manage conflicts of interest for both ministers and civil servants, including where these relate to engagement with representatives of unhealthy commodity industries.
Ministerial conduct is governed by the Ministerial Code, which sets out requirements on the declaration and handling of ministers’ interests. Civil servants are bound by the Civil Service Code, and by departmental policies that set out how actual, potential, or perceived conflicts of interest must be identified, declared, and managed.
The Department keeps its internal guidance under regular review to ensure it remains aligned with cross-Government standards and supports transparent and accountable decision-making.